These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 11984517)

  • 21. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
    Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
    Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
    J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
    Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study.
    Van Vlierberghe H; Adler M; Bastens B; Colle I; Delwaide J; Henrion J; Horsmans Y; Michielsen P; Golstein P; Mulkay JP; Van Steenbergen W; Yap P; Nevens F; Denys AM; Brasseur JP
    Acta Gastroenterol Belg; 2010; 73(1):5-11. PubMed ID: 20458844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
    Abergel A; Hezode C; Leroy V; Barange K; Bronowicki JP; Tran A; Alric L; Castera L; Bernard PH; Henquell C; Lafeuille H; Ughetto S; Darcha C; Chevallier M; Martineau N; Dubost S; Randl K; Dhumeaux D; Bommelaer G; Bonny C;
    J Viral Hepat; 2006 Dec; 13(12):811-20. PubMed ID: 17109680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
    Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
    Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
    Mucenic M; Brandão ABM; Marroni CA; Fleck Junior AM; Zanotelli ML; Leipnitz I; Meine MH; Kiss G; Martini J; Schlindwein ES; Costabeber AM; Sacco FKR; Rossato G; Cantisani GPC
    Rev Inst Med Trop Sao Paulo; 2019 Feb; 61():e12. PubMed ID: 30785566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M; Ouzan D; Rosenheim M; Doffoël M; Marcellin P; Pawlotsky JM; Salomon L; Fagnani F; Rouanet S; Pinta A; Vray M
    Antivir Ther; 2012; 17(1):101-10. PubMed ID: 22267474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
    Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.